Author: Ryan Allway

TORONTO, March 25, 2019 (GLOBE NEWSWIRE) — World Class Extractions Inc. (CSE: PUMP) (the “Company” or “World Class”) is pleased to announce that it has signed a definitive collaboration agreement (the “Collaboration Agreement”) with Parity Partners PBC (“Parity”), a corporation doing business in the State of North Carolina. The Collaboration Agreement sets forth the terms on which Parity will assist World Class in expanding its hemp and cannabis large scale extraction business in the United States.

Parity is co-founded by Bert James. Mr. James is a founding board member for the newly formed US Hemp Farming Alliance which is a partner organization with the US Hemp Round Table and the US Hemp Authority. He is the owner of Homegrown Agriculture Inc., since 2001, and the former CEO of Bio Regen Co-Op, an agricultural co-op with more than 100 farm members. Mr. James is a lead supporter and advocate of the North Carolina Industrial Hemp Program and is a featured speaker at hemp events across the United States.

In consideration for the various services that the parties intend to provide each other, as described below, the parties will split the net income arising out of the venture, with 75% being allocated to World Class and 25% to Parity. In addition, World Class has, as of the date hereof, granted Parity an aggregate of 40,000,000 warrants (“Warrants”) to purchase common shares in the capital of World Class (“Common Shares”). The Warrants vest in 5,000,000 increments upon the venture achieving certain gross revenue and net income thresholds, with each such increment having a different exercise price, all as described in the table below.

Milestones	Exercise Price
1	CAD$0.15
2	CAD$0.17
3	CAD$0.20
4	CAD$0.23
5	CAD$0.30
6	CAD$0.33
7	CAD$0.40
8	CAD$0.50

Parity Obligations

Under the terms of the Collaboration Agreement, Parity will be responsible for the following:

• sourcing appropriate locations in the United States to locate World Class’s proprietary extraction machines (the “WCE Machines”);
• obtaining all licenses and approvals necessary for World Class to extract oils containing THC, CBD, and other cannabinoids from hemp and cannabis plants (the “Extraction Services”); and
• supplying the raw materials necessary for World Class to perform the Extraction Services;
• developing a market for the Extraction Services and the products produced out of the Extraction Services, including by employing salespeople and developing relationships with distributors.

World Class Obligations

Under the terms of the Collaboration Agreement, World Class will be responsible for reimbursing Parity for the employment of Parity’s staff, other than its sales staff and paying for the delivery and installation of the WCE Machines.

Michael McCombie, Chief Executive Officer of World Class, stated, “This agreement represents a major milestone in expanding World Class’s business into the United States. We are absolutely thrilled to build upon World Class’s present success and momentum by taking our business into the United States. Parity will be a valuable partner, and World Class is excited to work together with Parity through strong collaboration and mutual commitments.”

Bert James, CEO of Parity, stated, “Parity Partners PBC is proud to be a part of the future of cannabis processing with World Class Extractions. The alignment, values and vision both companies offer the hemp industry is exciting. We will be a part of the new history being written about hemp and plant extracts.”

About World Class Extractions Inc.

The Company is a Canadian based developer of an innovative extraction process for both the hemp and cannabis industry. The Company intends to provide single step continuous flow extraction services to the hemp and cannabis industry. Using patent pending technology, the Company’s results produce higher yields and better quality crude hemp oil at faster rates. The technology allows the extraction of CBD Oil and other related extracts from wet or dried natural plants. The Company can save its clients floor space, utility drying costs, equipment and processing labour costs.

About Parity Partners PBC

The United States based Parity Partners PBC provides operational balance in agricultural production and further processing models. By utilizing a national network of trusted partners and service providers, combined with decades of related industry experience, clear paths are created to implement new and innovative technologies. Through collaboration and innovation, sustainable and regenerative practices find their way from the farmer’s field to the consumer’s counter. Parity promotes and facilitates open communication with supply chains and processors leading to increased efficiency and premium end products.

For further information please contact:

Michael McCombie
Chief Executive Officer
Email: mike@wcextractions.com

Forward Looking Statements

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.

TORONTO, March 25, 2019 — The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX: TGOD) (US: TGODF) is pleased to announce that effective today sales of certified-organic cannabis have started with national distribution to medical patients. The Growers’ Circle is a select group of patients across Canada now receiving TGOD’s first certified-organic flower. The Growers’ Circle launch is a limited production rollout of the Company’s premium product, allowing TGOD to perfect its distribution ahead of its production ramp-up and scaled rollout this year. “The launch of the Growers’ Circle is another significant moment in TGOD’s commercial story,” said Brian Athaide, Director and Chief Executive Officer. “Our certified-organic cannabis is a premium experience for patients. We are proud of our product and excited to be sharing it with Growers’ Circle members.” TGOD cannabis is grown in living soil without synthetic fertilizers, pesticides or herbicides. TGOD cannabis is certified-organic by ECOCERT and Pro-cert, pre-eminent global certification bodies. Hill & Knowlton consumer research confirmed that 60% of medical cannabis patients prefer certified-organic product. TGOD flower is packaged in recyclable glass jars and speaks to the Company’s product quality, sustainability and regenerative philosophy. TGOD is now shipping its Unite Organic strain to over 200 medical patients across Canada. “It’s been a rewarding experience to get to this point, talking with consumers and understanding their needs, through to growing and cultivating organic product,” said Csaba Reider, President of TGOD. “Growing organic requires patience, and we know that our cannabis was worth the wait.” TGOD Growers’ Circle members will receive a state-of-the-art online and app experience that provides timely information on individual medical needs. “We have spent months talking with consumers about their preferred cannabis experience,” said Andrew Pollock, Vice President of Marketing for TGOD. “We believe that through our website, the experience – from signup to follow-up, to ongoing care – will be the finest in the industry.” TGOD will be expanding the list of Growers’ Circle members as more supply comes online, as well as becoming a significant presence in the recreational market. On Behalf of the Board of Directors, The Green Organic Dutchman Holdings Ltd. CONTACT INFORMATION Investor Relations Email: invest@tgod.ca

ABOUT THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD. The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively. For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.

TALLAHASSEE, FL, March 21, 2019 /CNW/ – Trulieve Cannabis (OTC: TCNNF & CNSX: TRUL) (“Trulieve”), a leading and top performing cannabis company in the United States, was the first medical marijuana licensee in Florida to make a sale of smokable cannabis. The sale took place at Trulieve’s Tallahassee dispensary, the first dispensary to have opened in the state.

“We are excited about the opportunity to sell whole flower smokable products to patients in Florida and honored to be the first company in Florida to do so. Thank you to Governor DeSantis and the Legislature for taking up and approving smokable products in Florida and special thanks to the Department of Health and the Office of Medical Marijuana Use for their quick action to make today a reality for patients in need. Offering these whole flower products to our patients in their purest, most effective form is something we – and patients – have been looking forward to since we opened the doors of the state’s first dispensary,” said Trulieve CEO Kim Rivers.

Dr. Cheryl Fee, a Tallahassee-based physician, was the doctor to make the recommendation. Regarding the ability to recommend smokable cannabis for patients, she stated: “It’s an honor to be a part of the first sale and provide patients that need it this smokable whole-flower option.”

Trulieve’s smokable whole-flower buds will be the first product available and is offered in a rotating selection of popular strains.  Trulieve also plans to roll out smokable marijuana in a variety of forms, including pre-roll.

Presently, Trulieve operates 26 dispensaries throughout the state of Florida, spanning from Pensacola to Miami. As part of the company’s mission to ensure safe, reliable access for patients statewide, Trulieve plans to continue opening stores statewide as the patient registry and demand grows.

In stores and online, patients will find Florida’s largest selection of THC and CBD products, available in a variety of delivery methods, including flower for smoking and vaporizing, concentrates, tinctures, topical creams, vaporizers, and more. Trulieve also offers home delivery statewide for patients unable to make it to a physical store.

Recently, the Office of Medical Marijuana Use announced the registry had surpassed 190,000 registered medical marijuana patients with an active ID card, with Trulieve consistently selling between 60%-80% of the state’s overall volume, per the Florida Department of Health. There are currently more than 2,000 registered ordering physicians in the state of Florida as well.

About Trulieve
Trulieve Cannabis Corp. is a vertically integrated “seed to sale” company and is the first and largest fully licensed cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve also operates in California and Massachusetts.

Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL.

This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States and may not be offered or sold within the United States (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

To learn more about Trulieve, visit www.Trulieve.com.

SOURCE Trulieve Cannabis Corp.

For further information: Kevin Darmody, Director, Investor Relations, (850) 480-7955, IR@trulieve.com; Victoria Walker, Director of Marketing & Community Relations, (704) 773-3446, Victoria.Walker@trulieve.com

Vancouver, BC, March 22, 2019 (GLOBE NEWSWIRE) — INVICTUS MD STRATEGIES CORP. (“Invictus” or the “Company”) (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) is pleased to announce that the Company’s licensed producer AB Labs Inc. (“AB Labs”) has received a medical sales and processing license from Health Canada effective March 16, 2019, pursuant to the Cannabis Act and Cannabis Regulations (“CACR”). The newly awarded license allows for the sale of final packaged flower, plants and seeds to retailers, distributers and patients.

AB Labs, located in Hamilton, Ontario is at the heart of the Company’s presence in Eastern Canada, with its 16,000 square foot Phase 1 facility currently operating at full capacity, and its 40,000 square foot Phase 2 facility just weeks away from finalizing its Confirmation of Readiness submission to Health Canada. AB Labs’ research and development is also ongoing, with fifteen new strains expected to be added to Invictus’ product portfolio this year.

“We are proud to have achieved another major milestone with our third sales license awarded by Health Canada,” said George E. Kveton, President and CEO of Invictus. “We are looking forward to increasing our capacity at facilities across Canada in 2019 to ensure a consistent and substantial supply of products for recreational and medical patients alike.”

AB Labs represents the Company’s third cultivation license and third sales license issued by Health Canada under the Cannabis Act and Cannabis Regulations. Invictus’ production footprint includes licensed cannabis operations in British Columbia, Alberta and Ontario.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
George E. Kveton
Chief Executive Officer and Director

Jessica Martin
Vice President, Public Relations and Regulatory Affairs
(833) 879-4363

About Invictus

Invictus is a global cannabis company offering a selection of products under a wide range of brands. Our integrated sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores.

Invictus has partnered with business leaders to convey our corporate vision, including KISS music legend and business mogul Gene Simmons as our Chief Evangelist Officer. To meet growing demand, Invictus is expanding its cultivation footprint, with three cannabis production facilities licensed under the Cannabis Act and Cannabis Regulations in Canada. To accommodate international sales, Invictus’ wholly-owned subsidiary, Acreage Pharms Ltd. (“Acreage Pharms”), has designed and is currently building its Phase 3 purpose-built cultivation facility to be European Union Good Manufacturing Practices (“EU-GMP”) compliant. The Company is targeting up to 50 percent of production to medical cannabis. To ensure consistency in quality and supply, Invictus maintains all aspects of the growing process through its subsidiary, Future Harvest Development Ltd. (“Future Harvest”), a high-quality fertilizer and nutrients manufacturer. Invictus drives sustainable long-term shareholder value through a diversified product portfolio with over 70 Health Canada approved strains and a multifaceted distribution strategy including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores. For more information visit www.invictus-md.com.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including the AB Labs Phase 2 facility is anticipated to be weeks away from submitting its Confirmation of Readiness to Health Canada and that AB Labs is expected to add 15 new strains of cannabis to the Company’s product portfolio this year are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the AB Labs Phase 2 facility is weeks away from submitting its Confirmation of Readiness to Health Canada and that AB Labs will add 15 new strains of cannabis to the Company’s product portfolio this year. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, that the AB Labs Phase 2 facility will not submit its Confirmation of Readiness to Health Canada on the timeline anticipated by management or at all and that AB Labs will not add 15 new strains of cannabis to the Company’s product portfolio this year or at all. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Jessica Martin
Invictus 
(833) 879-4363
jessica@invictus-md.com

EDMONTON, March 22, 2019 /CNW/ – Fire & Flower Holdings Corp. (“Fire & Flower” or the “Company”) (TSXV: FAF), today announced stores operating under the Fire & Flower brand in Ottawa and Kingston have received both Retail Operator Licences and Retail Store Authorizations from the Alcohol and Gaming Commission of Ontario (the “AGCO”).

The store agreements with Ontario licence holders were previously announced by Fire & Flower on February 19, 2019.

“The store licence holders in Ottawa and Kingston worked closely with Fire & Flower’s retail and operations teams to obtain the store licenses and authorizations,” shared Trevor Fencott, Chief Executive Officer of Fire & Flower. “This announcement demonstrates Fire & Flower’s ability to rapidly open new markets as we expand our brand across Canada.”

About Fire & Flower
Fire & Flower is a leading purpose-built, independent adult-use cannabis retailer poised to capture significant Canadian market share. The Company guides consumers through the complex world of cannabis through education-focused, best-in-class retailing while the HiFyre digital platform connects consumers with cannabis products. The Company’s leadership team combines extensive experience in the cannabis industry with strong capabilities in retail operations.

 

Fire & Flower Holdings Corp. owns all issued and outstanding shares in Fire & Flower Inc., a licensed cannabis retailer in the provinces of Alberta and Saskatchewan and consultant to Fire & Flower-branded retail locations in province of Ontario.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking information within the meaning of applicable Canadian securities laws ( “forward-looking statements”). All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “project” and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions “may” or “will” occur. These statements are only predictions.

Forward-looking statements are based on the opinions and estimates of management of the Company at the date the statements are made based on information then available to the Company.  Various factors and assumptions are applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements.  Forward-looking statements are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. No assurance can be given that the expectations reflected in forward-looking statements will prove to be correct.

The Company assumes no obligation to publicly update or revise forward-looking statements to reflect new information, future events or otherwise, except as expressly required by applicable law.

SOURCE Fire & Flower Holdings Corp.

For further information: Nathan Mison, Vice President, Government and Stakeholder Relations, nmison@fireandflower.com, 780-953-1106

NAPANEE, ON, March 22, 2019 /CNW/ – VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) (“VIVO” or the “Company“) today announced that the Company’s wholly-owned subsidiary, Canna Farms Ltd. (“Canna Farms“), has received approval from Health Canada to begin cultivation in the expansion of its Yale Road facility in Hope, BC, resulting in a doubling of the Company’s cultivation capacity in the province.

The expansion includes production and product development space, along with automated packaging equipment expected to be incorporated into the facility and brought on-line mid 2019. Cultivation in the expanded area is expected to commence in May 2019.

“Today’s approval of the Hope, British Columbia expansion is in addition to the Napanee, Ontario capacity increase approved by Health Canada yesterday,” said Barry Fishman, Chief Executive Officer at VIVO. “With the additional cultivation from Hope, VIVO’s current annual production capacity is now more than 8,000 kilograms with a goal to reach 11,000 kilograms later in 2019.”

Dan Laflamme, Canna Farms President and Chief Operations Officer for VIVO added, “While we continue to grow production capacity at Canna Farms, we remain committed to being able to deliver craft quality BC bud. Through small-batch growing techniques, Canna Farms offers a varied selection of award-winning, hand-trimmed cannabis for both medical and adult-use products. As BC’s first licensed producer, we are proud of our legacy and reputation for quality, which remains our first priority.”

About VIVO Cannabis

VIVO, based in Napanee, Ontario, is recognized for trusted, high-quality products and services. It holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities with proprietary plant-growing technology. VIVO has a collection of premium brands targeting unique customer segments, including Beacon Medical, FIRESIDE, Canna Farms and Lumina. In August 2018, VIVO acquired Canna Farms, a premium cannabis company based in Hope, British Columbia. Canna Farms was B.C.’s first Licensed Producer and has several years of craft cultivation experience and expertise, as well as a significant patient base and positive cash flow. The Company is significantly expanding its production capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, including Germany and Australia. VIVO also operates Harvest Medicine, a patient-centric and highly scalable network of specialty medical cannabis clinics as well as a free telemedicine app. VIVO has a healthy balance sheet and is well-positioned to accelerate its growth in Canada and internationally.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements, which are statements that are not purely historical, regarding the beliefs, plans, expectations or intentions of the Company and its management regarding the future, and should not be read as guarantees of future performance or results. Forward looking statements in this news release include statements regarding: the expected amount and timing of realization of increased production capacity as a result of the Hope expansion and the sourcing of product from third party cultivators; the expected timing of completion of the next phase of the Hope expansion; and the Company’s international growth plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: mechanical or crop failures at the Hope facility that cause the Company to fail to attain its expected production targets; failure of the Company to agree on acceptable terms with third party cultivators; construction or regulatory delays with respect to the next phase of the Hope expansion; potential delays in producing saleable finished products or bringing new product lines to market; and other factors beyond the Company’s control. A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s Annual Information Form for the year ended December 31, 2017 and other continuous disclosure filings, which are available on SEDAR at www.sedar.com. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company disclaims any intention or obligation to update or revise any forward-looking statements as a result of new information or future events, or for any other reason, other than as required by applicable securities laws.

SOURCE VIVO Cannabis Inc.

For further information: VIVO Investor Relations, Heidi Christensen Brown, +1.416-848-1389, hchristensenbrown@national.ca, NATIONAL Capital Markets; Michael Bumby, Chief Financial Officer, michael.bumby@vivocannabis.com, VIVO Cannabis Inc.

Related Links

https://www.vivocannabis.com/

NAPANEE, ON, March 21, 2019 /CNW/ – VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) (“VIVO” or the “Company“) today announced that the Company’s wholly-owned subsidiary, ABcann Medicinals Inc., has received approval from Health Canada to begin cultivation in the expansion of its Vanluven Road facility in Napanee, resulting in a doubling of the Company’s Ontario cultivation capacity. Cultivation in the expanded area will commence immediately.

The expansion includes production and product development space built to GMP standards. A supercritical CO2 extraction suite for production of concentrates has been incorporated into the facility and is expected to be brought on-line mid 2019. VIVO’s current production capacity is now over 5,000 kilograms and is anticipated to further increase to 11,000 kilograms later in 2019 following the completion and licensing of on-going, fully-funded expansion projects in Hope, B.C. and Napanee, Ontario. This capacity will be augmented by several thousand additional kilograms sourced from third-party cultivators that meet VIVO’s rigorous quality standards.

“Through our internal expansion projects (including indoor facilities, seasonal greenhouses and outdoor growing) and certified third-party partners, we are well-positioned to increase our offering of premium products in Canada’s medical and adult-use markets, including launching new formats such as edibles, concentrates and precisely-dosed medical products when they are permitted by regulations,” said Barry Fishman, Chief Executive Officer of VIVO.

Mr. Fishman added, “The GMP certification of our Vanluven expansion, expected later this year, will enable us to service the growing international medical cannabis market. We are excited to build on our success by introducing new high-margin, value-added products which leverage our increased production capabilities and tap into the user insights gained from our vast Harvest Medicine Clinic patient network.”

About VIVO Cannabis

VIVO, based in Napanee, Ontario, is recognized for trusted, high-quality products and services. It holds production and sales licences from Health Canada and operates world-class indoor cultivation facilities with proprietary plant-growing technology. VIVO has a collection of premium brands targeting unique customer segments, including Beacon Medical, FIRESIDE, Canna Farms and Lumina. In August 2018, VIVO acquired Canna Farms, a premium cannabis company based in Hope, British Columbia. Canna Farms was B.C.’s first Licensed Producer and has several years of craft cultivation experience and expertise, as well as a significant patient base and positive cash flow. The Company is significantly expanding its production capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, including Germany and Australia. VIVO also operates Harvest Medicine, a patient-centric and highly scalable network of specialty medical cannabis clinics as well as a free telemedicine app. VIVO has a healthy balance sheet and is well-positioned to accelerate its growth in Canada and internationally.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements, which are statements that are not purely historical, regarding the beliefs, plans, expectations or intentions of the Company and its management regarding the future, and should not be read as guarantees of future performance or results. Forward looking statements in this news release include statements regarding: the expected amount and timing of realization of increased production capacity as a result of the Vanluven expansion and the sourcing of product from third party cultivators; the expected timing of completion of the next phase of the Vanluven expansion; and the Company’s international growth plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: mechanical or crop failures at the Vanluven facility that cause the Company to fail to attain its expected production targets; failure of the Company to agree on acceptable terms with third party cultivators; construction or regulatory delays with respect to the next phase of the Vanluven expansion; potential delays in producing saleable finished products or bringing new product lines to market; and other factors beyond the Company’s control. A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s Annual Information Form for the year ended December 31, 2017 and other continuous disclosure filings, which are available on SEDAR at www.sedar.com. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company disclaims any intention or obligation to update or revise any forward-looking statements as a result of new information or future events, or for any other reason, other than as required by applicable securities laws.

SOURCE VIVO Cannabis Inc.

For further information: VIVO Investor Relations: Heidi Christensen Brown, +1.416-848-1389, hchristensenbrown@national.ca, NATIONAL Capital Markets; Michael Bumby, Chief Financial Officer, michael.bumby@vivocannabis.com, VIVO Cannabis Inc.

Related Links

https://www.vivocannabis.com/

OTTAWA, March 22, 2019 /CNW/ – CannaRoyalty Corp. d/b/a Origin House (CSE: OH) (OTCQX: ORHOF) (“Origin House” or the “Company”), a North American cannabis products and brands company today announced that the Company’s wholly owned subsidiaries, Kaya Management Inc. (“Kaya”) and FloraCal® Farms (“FloraCal”), were awarded annual operating licenses from the State of California.

Kaya operates a licensed manufacturing facility in Oakland, California that manufactures edibles, vaporizers and pre-rolls, and was issued an annual Type 6 non-volatile manufacturing license by the California Department of Public Health. Approximately 60 cannabis manufacturing facilities across California have received annual licenses.

FloraCal operates a craft cannabis cultivation facility located in Sonoma County, California and was issued a one-year provisional cultivation license,¹ from the California Department of Food and Agriculture. This is the first annual or provisional cultivation license to be issued in Sonoma County.

Origin House currently operates five licensed facilities across California. Kaya and FloraCal are the first of those facilities to transition from temporary to annual licensure.

About Origin House

Origin House is a growing cannabis products and brands company operating across key markets in the U.S. and Canada, with a strategic focus on becoming a preeminent global house of cannabis brands. The Company’s foundation is in California, the world’s largest regulated cannabis market, where it delivers over 130 branded cannabis products to the majority of licensed dispensaries. Origin House’s brand development platform is operated out of five licensed facilities located across California, and provides distribution, manufacturing, cultivation and marketing services for its brand partners. The Company is actively developing infrastructure to support the proliferation of its brands internationally, initially through its acquisition of Canadian retailer 180 Smoke. Origin House’s shares trade on the Canadian Securities Exchange (CSE) under the symbol “OH” and on the OTCQX under the symbol “ORHOF”. Origin House is the registered business name of CannaRoyalty Corp. For more information, visit www.originhouse.com.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Origin House’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward- looking statements.

Forward-looking statements may include, without limitation, statements relating to the timing and completion of the transactions and agreements contemplated in this press release, the execution of the Company’s strategy, new opportunities, the Company’s timing and process for expansion in Canada and globally, timing for the Company’s acquisition of 180 Smoke, new opportunities, future growth and other statements. 

Although the Company has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects that are engaged in activities currently considered illegal under US federal law; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. The Company disclaims any intention or obligation to update or revise such information, except as required by applicable law, and the Company does not assume any liability for disclosure relating to any other company mentioned herein.

NEW YORK, March 18, 2019 /CNW/ – iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN) (OTCQX: ITHUF), which owns, operates, and partners with best-in-class regulated cannabis operations across the United States, is pleased to announce that it has completed the private placement offering of US$35 million of unsecured convertible notes and corresponding warrants to three investors (the “Offering”). The proceeds from the Offering will be applied to continue the build-out of facilities across the Company’s 11-state footprint.

“With the closing of the transaction with MPX Bioceutical Corporation in early February, iAnthus remains driven to become a market leader across our 11-state platform. This financing allows the Company to simultaneously strengthen our balance sheet, deepen our investor base, and fund our growth capital,” said Hadley Ford, CEO of iAnthus.

The Company has issued units consisting of US$35 million aggregate principal amount of unsecured convertible notes, with a maturity date of four years (the “Notes”) and 2,177,291 warrants (“Warrants”) to purchase common shares of the Company (“Common Shares”). Additionally, until April 26, 2019, one of the noteholders shall have the right to purchase up to an additional US$25 million aggregate principal amount of Notes and corresponding Warrants.

The Notes accrue interest at the rate of 8% per annum, payable quarterly, which may, at the Company’s option, be paid up to 50% in common shares of the Company (“Common Shares”) for two years following closing. The Notes are convertible into an aggregate of 5,912,160 Common Shares at US$5.92 per Common Share. At any time following July 16, 2019, iAnthus may force the conversion of the Notes into Common Shares if the daily volume weighted average trading price of the Common Shares on the OTCQX is greater than US$10.29 for any ten consecutive trading days. Each Warrant entitles the holder thereof to acquire one Common Shares at an exercise price of US$6.43 per Common Share for a period of 36 months from the closing date.

GMP is acting as the exclusive financial advisor to iAnthus. The Company has agreed to pay a finder fee to one party, of US$1.2 million, of which 50% is payable in cash and 50% is payable through the issuance of 116,600 Common Shares.

Following the transaction, iAnthus’ cash balance exceeds $50 million, and the Company has a total of 158,069,719 basic shares and 233,300,155 fully diluted shares outstanding, respectively.

The Notes and Warrants issued pursuant to the Offering and any Common Shares issued on conversion of the Notes or exercise of the Warrants are subject to a statutory hold period in Canada of four months and one day following the closing date in accordance with applicable securities laws, which shall expire on July 16, 2019. Additional resale restriction may be applicable under the laws of other jurisdictions, if any.

About iAnthus Capital Holdings, Inc.

iAnthus Capital Holdings, Inc. owns and operates best-in-class licensed cannabis cultivation, processing and dispensary facilities throughout the United States, providing investors diversified exposure to the U.S. regulated cannabis industry. Founded by entrepreneurs with decades of experience in operations, investment banking, corporate finance, law and health care services, iAnthus provides a unique combination of capital and hands-on operating and management expertise. iAnthus currently has operations in 11 states, and operates 21 dispensaries (AZ-4, MA-1, MD-3, FL-3, NY-2, CO-1, VT-1 and NM-6 where iAnthus has minority ownership). For more information, visit www.iAnthusCapital.com.

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in iAnthus’ periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should, our vision” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements including the use of proceeds from the Offering, the purchase of additional Notes and Warrants under the Offering, dispensary locations, facility build-outs, and other statements of fact.

Readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. iAnthus disclaims any intention or obligation to update or revise such information, except as required by applicable law, and iAnthus does not assume any liability for disclosure relating to any other company mentioned herein.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

SOURCE iAnthus Capital Holdings, Inc.

For further information: Corporate: Julius Kalcevich, Chief Financial Officer, iAnthus Capital Holdings, Inc., 646-518-9411, investors@ianthuscapital.com; US Investors: Phil Carlson / Elizabeth Barker, KCSA Strategic Communications, iAnthus@KCSA.com; Canadian Investors: investors@ianthuscapital.com; Media:Robert Vanisko, North 6th Agency, 212-334-9753 ext.112, iAnthus@n6a.com

Related Links

https://www.ianthuscapital.com/

LOS ANGELES–(BUSINESS WIRE)–MedMen Enterprises Inc. (CSE:MMEN) (OTCQX:MMNFF) (FSE: A2JM6N) (“MedMen” or the “Company”), is pleased to announce that it has signed a binding term sheet for a senior secured convertible credit facility of up to US$250,000,000 (the “Facility”) from funds managed by Gotham Green Partners (“GGP” or the “Investor”), an investor in the global cannabis industry. Management believes this is the largest investment to date by a single investor in a publicly traded cannabis company with U.S. operations.

“The growth capital will be used to operationalize the balance of our footprint and we look forward to creating further alignment with GGP and their global cannabis platform.”

Tweet this

“This strategic partnership with Gotham Green Partners represents another key milestone for MedMen and stems from our long-standing relationship with The Cronos Group and GGP’s brand portfolio,” said Adam Bierman, CEO of MedMen. “The growth capital will be used to operationalize the balance of our footprint and we look forward to creating further alignment with GGP and their global cannabis platform.”

“We continue to be impressed with MedMen’s industry leading retail execution and iconic branding. With MedMen’s fortified balance sheet, the Company’s future has never been brighter,” said Jason Adler, managing member of GGP. “We feel fortunate to have the opportunity to take such a significant stake in MedMen and begin to work actively with the management team and the board to help the Company achieve its goals.”

The Company intends to use the net proceeds from drawdowns on the Facility to fund the future capital needs of the business. In addition to funding general working capital, the growth capital will primarily be used to:

• Operationalize existing retail licenses, with a focus on Florida, where the Company is licensed for 30 stores
• Integrate assets acquired through pending transactions, including those related to PharmaCann, LLC
• Accelerate geographic expansion through bolt-on acquisitions and investments in core markets
• Support national roll-out of higher-margin in-house branded products
• Continue to invest in technology and digital infrastructure, with a focus on delivery and loyalty programs
• Consolidate the supply chain and enhance margins by ramping up cultivation and production capabilities

The investment from GGP will be in the form of convertible senior secured notes issued by MM CAN USA, Inc., a subsidiary of the Company, totaling up to US$250,000,000 (“Notes”) on a private placement basis pursuant to applicable securities laws exemptions. The Notes will be issuable in three tranches, with each of the second and third tranches being issuable at the option of the Company, subject to certain conditions and share price thresholds being achieved by MedMen. The initial tranche will be in the amount of US$100,000,000 (“Tranche I”). The additional US$150,000,000 would be funded in two US$75,000,000 tranches. The second tranche (“Tranche II”) would be available to the Company beginning on the six-month anniversary of the closing date, and the third tranche (“Tranche III”) would be available to the Company beginning on the six-month anniversary of the funding date of Tranche II.

All Notes will have a maturity date of 36 months from the closing date (“Maturity Date”), with a 12-month extension feature available to the Company on certain conditions, including payment of an extension fee. Notes will bear interest from their date of issue at LIBOR + 6.0% per annum. During the first 12 months, interest may be paid-in-kind (“PIK”) at the Company’s option such that any amount of PIK interest will be added to the outstanding principal of the Notes. The Company shall have the right after the first year, to prepay the outstanding principal amount of the Notes prior to maturity, in whole or in part, upon payment of 105% of the principal amount in the second year and 103% of the principal amount thereafter.

All or a portion of the Notes (including all accrued interest thereon) will be convertible, at the option of the holder, into class B subordinate voting shares of the Company (the “Subordinate Voting Shares”) at any time prior to the close of business on the last business day immediately preceding the Maturity Date. The conversion price of each tranche of Notes is as follows:

i) for Tranche I Notes, the conversion price will be equal to 115% of the lesser of (the “Tranche I Reference Price”) (a) US$3.10, which represents the closing price of the Subordinate Voting Shares on the Canadian Securities Exchange (the “CSE”) on the trading day immediately preceding the announcement of the Facility (translated to US dollars), and (b) the closing price of the Subordinate Voting Shares on the trading day immediately preceding the closing date; and

ii) for Tranche II and Tranche III Notes, the conversion price will be equal to the lesser of (a) 115% of the 20 trading day volume weighted average trading price of the Subordinate Voting Shares as of the trading day immediately preceding the date of issue of such tranche, and (b) US$7.00.

The Company may force the conversion of up to 75% of the then outstanding Notes at the applicable conversion price(s) if the volume weighted average trading price of the Subordinate Voting Shares (translated to US dollars) is US$8.00 for any 20 consecutive trading day period. If 75% of the then outstanding Notes are converted by the Company, the term of the remaining 25% of the then outstanding Notes will be extended by 12 months.

Upon drawdown of Tranche I, the lenders would be issued share purchase warrants (“Warrants”), each of which would be exercisable to purchase one Subordinate Voting Share. The number of Warrants to be issued will represent an approximate 50% Warrant coverage on the Tranche 1 Notes, certain of which Warrants will have an exercise price per Subordinate Voting Share that will be equal to a 30% premium to the Tranche I Reference Price, and another group of which Warrants will have an exercise price per Subordinate Voting Share that will be equal to a 50% premium to the Tranche I Reference Price. The Warrant coverage on the Tranche II and Tranche III Notes will be similar to those for the Tranche I Notes. The exercise prices for the Warrants on the Tranche II and Tranche III Notes will be equal to the lesser of (a) a 30% or 50% (as the case may be) premium to the 20 trading day volume weighted average trading price of the Subordinate Voting Shares as of the trading day immediately preceding the date of the drawdowns of such tranches, and (b) US$7.91 or US$9.13 (as the case may be).

The Warrants and any Subordinate Voting Shares issuable upon conversion of the Notes or exercise of the Warrants, will be subject to a four month hold period from the date of issuance of the Notes or such Warrants, as applicable, in accordance with applicable Canadian securities laws.

The terms of the Facility described in this press release are those set out in a binding term sheet. However, completion of any tranche is subject to further agreements being entered into by the parties, including as to the guarantees and/or the collateral to be provided by MedMen and its applicable subsidiaries to secure its obligations under the Facility. The terms of the Facility, the Notes and the Warrants and the conditions to drawdowns are subject to change as the parties negotiate such definitive documentation. The closing of any tranches will be subject to certain conditions being satisfied including, but not limited to, the receipt of all necessary approvals and the absence of material adverse changes. The parties are currently anticipating a closing in April. There can be no assurance that the parties will enter into definitive documentation such that the Facility will be available, or if definitive documentation is entered into, that the terms of the Facility, the Notes and the Warrants and the conditions to receiving the proceeds of any of the tranches will be as stated above.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

ABOUT MEDMEN:
MedMen is a cannabis retailer with operations across the U.S. and flagship stores in Los Angeles, Las Vegas and New York. MedMen’s mission is to provide an unparalleled experience that invites the world to discover the remarkable benefits of cannabis because a world where cannabis is legal and regulated is a safer, healthier and happier world. Learn more at www.medmen.com

ABOUT GOTHAM GREEN PARTNERS:
Gotham Green Partners, LLC is a New York and California-based private equity firm focused on deploying capital into cannabis and cannabis-related enterprises on a global scale. The firm manages a diversified portfolio of investments and is actively investing across the cannabis value chain.

SOURCE: MedMen Enterprises

Cautionary Note Regarding Forward-Looking Information and Statements:

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only MedMen’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of MedMen’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but is not limited to, expectations that definitive documentation for the Facility will be entered into, information concerning the terms of the proposed Facility, Notes and Warrants, timing for completion of Tranche 1 of the Facility, the use of proceeds of the Facility and the impact of such use of proceeds of the Facility on the business, assets, liabilities, financial condition, performance and prospects of MedMen.

By identifying such information and statements in this manner, MedMen is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedMen to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, MedMen has made certain assumptions. Although MedMen believes that the assumptions used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. Key assumptions used herein are that the parties will negotiate mutually acceptable definitive documentation, that the Facility will be entered into, that the current terms and anticipated timing will not change and that MedMen will be able to satisfy the conditions to drawdown on Tranche II and Tranche III of the Facility. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and MedMen does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to MedMen or persons acting on its behalf is expressly qualified in its entirety by this notice.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Contacts

OFFICER:
Adam Bierman, 855-292-8399
Chief Executive Officer
info@medmen.com

MEDIA CONTACT:
Briana Chester
Director of Public Relations
Email: briana.chester@medmen.com
(424) 888-4260

INVESTOR RELATIONS CONTACT:
Stéphanie Van Hassel
VP of Investor Relations
Email: investors@medmen.com
(323) 705-3025

TORONTO and VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) — World Class Extractions Inc. (“World Class”) (CSE: PUMP) and Quadron Cannatech Corporation (“Quadron”) (CSE: QCC) are pleased to announce that they have entered into a binding letter of intent (the “LOI”) to proceed with a business combination by way of a statutory plan of arrangement under the Business Corporations Act (British Columbia) pursuant to which World Class has agreed to acquire, either directly or through a wholly-owned subsidiary, all of the issued and outstanding common shares of Quadron (the “Arrangement”).

Under the terms of the LOI, on completion of the Arrangement, the shareholders of Quadron (the “Quadron Shareholders”) will receive two common shares (the “Exchange Ratio”) of World Class (a “World Class Share”) for each common share of Quadron (a “Quadron Share”) held. On closing of the Arrangement, it is expected that the current Quadron Shareholders will receive approximately 143,300,894 World Class Shares. Concurrently with the closing of the Arrangement, the holders of options and warrants in the capital of Quadron will receive a proportionate number of options and warrants of World Class.

Final terms of the Arrangement will be set out in an arrangement agreement (the “Arrangement Agreement”) to be entered into by the parties. The Arrangement Agreement will contain representations and warranties for the benefit of each of World Class and Quadron, conditions relating to shareholder, court and regulatory approvals, material adverse changes and compliance with the Arrangement Agreement as are in each case customary in comparable transactions of this nature. The Arrangement Agreement will include, among other things, a non-solicitation covenant on the part of Quadron (subject to customary fiduciary out provisions). In the event of a superior proposal, World Class will have the right to either match such superior proposal or receive a termination fee to be agreed by the parties in the Arrangement Agreement, commensurate with transactions of a similar size.

Completion of the Arrangement is subject to a number of conditions being satisfied or waived by one or both of World Class and Quadron at or prior to closing of the Arrangement, including: entry into the Arrangement Agreement; approval of the Quadron Shareholders, together with any requisite minority approvals; and receipt of all necessary regulatory and court approvals and the satisfaction of certain other closing conditions customary for a transaction of this nature. Quadron intends to engage an independent financial advisor to assist the Board of Directors and to provide a fairness opinion, if advisable.

Directors, officers and certain shareholders of Quadron representing 23% of the issued and outstanding Quadron Shares have agreed to enter into voting and support agreements under which they will agree to vote in favour of the Arrangement.

Details of the Arrangement, including a summary of the terms and conditions of the Arrangement Agreement, will be disclosed in a management information circular of Quadron, which will be mailed to Quadron Shareholders and will also be available on SEDAR at www.sedar.com.

Transaction Highlights

The proposed Arrangement is intended to create a leading provider of extraction and processing solutions. The combined entities will leverage Quadron’s technical expertise, established customer base and deep management team with World Class’s unique patent-pending technology and strong cash position resulting from its recent $23,000,000 private placement. The proposed Arrangement would produce the following synergies:

Quadron’s extraction and processing systems, which are automated and have been simplified relative to comparable technologies;
a deep roster of Quadron executives and employees that have been operating in the extraction and processing sector for over four years;
an established and growing revenue stream, as demonstrated by Quadron’s revenue increasing by 50.71% for the six months ended October 31, 2018 when compared to the same period in 2017;
World Class’s unique patent-pending technology, which World Class anticipates will provide higher yields of full spectrum cannabis oil at faster rates and larger volumes than current extraction technologies; and
a strong cash position resulting from World Class’s recently-closed private placement for gross proceeds of approximately $23,000,000.

Rosy Mondin, CEO of Quadron, stated, “We are very excited to proceed with this strategic alliance with World Class and believe it marks a definitive shift in our business model. Since our launch, Quadron’s focus has been the development of extraction and processing solutions to simplify and automate the very complex extraction process for cultivators. As the industry prepares for the legalization and regulation of cannabis concentrates and edibles in Canada, this transaction provides the necessary resources to increase sales, distribution and establish partnerships with leaders in industry with WCE, which will provide a significant growth opportunity for our shareholders. This merger combines the strength of both companies to strategically position them as leading global extractions solutions provider for cultivators and processors both within Canada and internationally to serve a rapidly growing cannabis oils market.”

Michael McCombie, Chief Executive Officer of World Class, added, “The combination of our business with Quadron’s gives us an opportunity to accelerate our goal of becoming the global leader in extraction and processing in general, with a particular focus on large-scale processing of CBD from hemp. We believe that our strong cash position and unique patent-pending technology, which can use both wet and dry cannabis and hemp as inputs, is the perfect complement to Quadron’s experienced team of executives and employees, along with their proven year-over-year revenue increases. This transaction is transformative for World Class and its shareholders, and we couldn’t be happier to be able to announce it on our first day of being listed on the CSE.”

The Arrangement is an arm’s length transaction pursuant to applicable regulatory policies.

This announcement is for informational purposes only and does not constitute an offer to purchase, a solicitation of an offer to sell any shares or a solicitation of a proxy.

About Quadron:
Quadron, through its wholly owned subsidiaries, provides turn-key extraction and processing solutions for the cannabis industry including proprietary industrial grade equipment, custom build processing facilities, ancillary products, and scientific services. Quadron delivers streamlined, cost-effective and innovative solutions to help licensed growers, producers and processors develop market ready products all to achieve quicker ROI.

For more information, visit: www.quadroncannatech.com

On behalf of the Board of Directors of
QUADRON CANNATECH CORPORATION

Rosy Mondin
CEO
rosy@quadroncannatech.com

Investor Relations Contact:
KIN Communications Inc.
Caleb Jeffries, VP, Investor Relations
1-866-684-6730
QCC@kincommunications.com

About World Class Extractions Inc.

The Company is a Canadian based developer of an innovative extraction process for both the hemp and cannabis industry. The Company intends to provide single step continuous flow extraction services to the hemp and cannabis industry. Using patent pending technology, the Company’s results produce higher yields and better quality crude hemp oil at faster rates. The technology allows the extraction of CBD Oil and other related extracts from wet or dried natural plants. The Company can save its clients floor space, utility drying costs, equipment and processing labour costs.

For further information please contact:

Michael McCombie
Chief Executive Officer
Email: mike@wcextractions.com

Neither the CSE nor its Market Regulatory (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions, including the proposed Arrangement will receive the requisite corporate and regulatory approvals, the proposed Arrangement will successfully close as anticipated by management, the holders of, the directors, officers and insiders of Quadron will enter into voting support agreements to vote in favor of the proposed Arrangement and Quadron will hire financial advisors are forward-looking statements and contain forward-looking information. Forward-looking statements are based on certain material assumptions and analysis made by World Class and Quadron and the opinions and estimates of management as of the date of this press release, including that the proposed Arrangement will receive the requisite corporate and regulatory approvals to close, the proposed Arrangement will successfully close on the timeline and on the terms as anticipated by management, market conditions will remain similar to present market conditions, that the directors, officers and insiders of Quadron will not object to signing an agreement to vote their shares in favor of the proposed Arrangement, Quadron will hire financial advisors and that the proposed synergies resulting from the combined entities will occur as stated or at all. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of World Class and Quadron to be materially different from those expressed or implied by such forward-looking statements or forward- looking information. Important factors that may cause actual results to vary, include, without limitation, the proposed Arrangement will not receive either the requisite corporate or regulatory approval to close, the proposed Arrangement will not close on the timeline or on the terms as anticipated by management, that the directors, officers and insiders of Quadron will object to signing an agreement to vote their shares in favor of the proposed Arrangement, Quadron will not hire financial advisors and the proposed synergies of the combined entities will not be realized as stated above or at all. Although management of Quadron and World Class have attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward- looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Quadron and World Class do not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

TORONTO, March 20, 2019 (GLOBE NEWSWIRE) — World Class Extractions Inc. (formerly, CBD Med Research Corp.) (“WorldClass” or the “Company”) is pleased to announce that the Canadian Securities Exchange (the “CSE”) has provided final approval to list the Company’s common shares (“Common Shares”) for trading. The Common Shares will commence trading at the opening of the market on Thursday, March 21, 2019 under the stock symbol “PUMP”. As noted in the Company’s press release of March 11, 2019, the net proceeds of the Company’s $23,000,000 subscription receipt financing have been released to the Company, which leaves it well-capitalized for the conduct of business.

World Class provides complete stationary and mobile cannabis and hemp extraction systems in North America and Europe. Using patent-pending technology, World Class anticipates higher yields of full spectrum cannabis oil at faster rates and larger volumes then current extraction technologies. Its technology was influenced by the petroleum processing industry, and is designed to be an industrial, scalable, continuous flow extraction process that can use both wet and dry cannabis/hemp as inputs.

Michael McCombie, Chief Executive Officer of World Class, stated, “Listing on the CSE is a major milestone for World Class, it allows us to provide liquidity for our loyal existing investors and gives us enhanced access to the capital markets. With our listing achieved, our team can now turn its entire efforts to what really matters – building out our core business, with a view to becoming a leader in the extraction sector.”

Corporate Secretary

The Company is also pleased to announce that, effective immediately, it has appointed Shimmy Posen as its Corporate Secretary. Mr. Posen is a lawyer at Garfinkle Biderman LLP, focused on helping companies go public and raise funds in the capital markets. His areas of expertise are corporate finance, mergers and acquisitions, and securities law. Mr. Posen has previously acted for public and private companies, securities dealers and financial institutions on a number of public and private financings and commercial transactions. Mr. Posen holds a J.D. from Osgoode Hall Law School and a B.A. in Political Science from York University.

Stock Options and Warrants

In addition to the CSE listing, the Company also announces the grant of an aggregate of 10,600,000 stock options and 5,600,000 Common Share purchase warrants to certain directors, officers, employees and consultants. The stock options and warrants each entitle the holders thereof to acquire one Common Share for a period of two years.

About World Class Extractions Inc.

The Company is a Canadian based developer of an innovative extraction process for both the hemp and cannabis industry. The Company intends to provide single step continuous flow extraction services to the hemp and cannabis industry. Using patent pending technology, the Company’s results produce higher yields and better-quality crude hemp oil at faster rates. The technology allows the extraction of CBD Oil and other related extracts from wet or dried natural plants. The Company can save its clients floor space, utility drying costs, equipment and processing labour costs.

Information concerning the Company and its previously announced business combination can be found in the Company’s listing statement dated March 14, 2019, which is located at the Company’s profile at www.sedar.com and on the Company’s profile on the CSE website.

Forward-Looking Statements

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward- looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

NEW YORK, March 19, 2019 /PRNewswire/ — Navy Capital, a New York-based asset manager focused on the rapidly growing global cannabis sector, has hired Chetan Gulati, who will join the firm as a Partner and Head of Research. Mr. Gulati brings nearly 20 years of experience to Navy’s team, having begun his career practicing law at Wachtell, Lipton, Rosen and Katz where he focused on corporate restructurings and finance. He then joined Perry Capital in 2007, and was ultimately appointed to run Perry’s London operations from 2010-2016. Most recently, Mr. Gulati was a Partner at Smith Cove Capital. He holds a BA from the University of Rochester and a JD from Yale Law School.

“We are delighted to welcome Chetan to our growing team,” said John T. Kaden, President and Managing Partner of Navy Capital. “His substantial experience in the industry will be a tremendous asset to Navy Capital at a time when institutional investors are increasingly looking for ways to gain exposure to secular trends in the global cannabis industry. We are committed to identifying the most attractive opportunities around the globe for our investors, and Chetan will play an integral part in leading that charge.”

“I am thrilled to join John and Sean at Navy Capital and look forward to furthering their presence as the thought leader in the global cannabis sector,” said Mr. Gulati. “Navy’s expertise and relationships in the industry are second to none, and the growing institutional investor interest and historic growth rates in the cannabis space make their positioning extremely attractive.”

In addition to Mr. Gulati, Navy Capital has also recently hired Kevin McLaughlin as CFO and Jaci Daudt as Director of Investor Relations. Mr. McLaughlin brings over 25 years of experience in CFO and CCO roles in the hedge fund industry, while Ms. Daudt brings nearly 10 years of industry experience and will lead the firm’s IR effort. In conjunction with the recent additions to the team, Sean Stiefel (Navy Capital’s Co-Founder and Portfolio Manager) has assumed the role of Chief Executive Officer, while Peter Watts (Head Trader) and Jeffrey Schultz (General Counsel) have been named partners of the firm.

About Navy Capital

Navy Capital is a research-oriented, fundamental-driven investment manager focused on identifying best-in-class opportunities, both Public and Private, within the global cannabis sector. Navy seeks to make investments in companies profiting directly or indirectly from the legalization of adult-use and medicinal cannabis.

575 Lexington Avenue, 4th Floor
New York, New York 10022
Tel: +1 (646) 916-4878 
Email: ir@navycapital.com

SOURCE Navy Capital Green Management, LLC

Reported Managed Revenue^([1]) of $87.8 Million in Full Year 2018 and $34.9 Million in Fourth Quarter through Continued Expansion of Market-Leading Operational Footprint

Demonstrated Managed Revenue Growth of 209% Year-over-Year and 43% Growth Quarter-over-Quarter

Reached Total Revenue of $77.1 Million in Full Year 2018 and $32.0 Million in Fourth Quarter

Reiterated Full Year 2019 Managed Revenue Guidance of $400 Million

WAKEFIELD, Mass., March 20, 2019 /PRNewswire/ — Curaleaf Holdings, Inc. (CSE: CURA) (OTC: CURLF), a leading vertically integrated cannabis operator in the U.S., today reported its financial and operating results for the fourth quarter and full year ended December 31, 2018. All financial information is provided in U.S. dollars unless otherwise indicated.

Q4 2018 and Full Year Financial Highlights (Unaudited)

Fourth Quarter Highlights

• Raised $400 million in a private placement offering and debuted as a public company on the Canadian Securities Exchange on October 29, 2018
• Managed Revenue⁽¹⁾ grew to $34.9 million, up 43% over the prior quarter
• Total Revenue reached $32.0 million, representing 49% growth over the prior quarter
• Adjusted EBITDA⁽¹⁾ of $(3.4) million compared to $(2.8) million in the prior quarter
• Building on existing licenses and prior acquisitions, Curaleaf opened seven new dispensaries at a rapid pace in key markets such as Florida and Arizona during the quarter
• Became the first multi-state operator to launch a national CBD product line, Curaleaf Hemp, which is currently available in major retail stores across the U.S.

Full Year Highlights

• Expanded presence to 12 states, with a focus on highly populated, limited-license states, including Arizona and Maryland
• Curaleaf operated 36 dispensaries, 12 cultivation sites and 10 processing sites as of December 31, 2018
• Managed Revenue grew to $87.8 million in full year 2018, up 209% on a year-over-year basis, and Total Revenue increased 298%, driven by a combination of organic growth and acquisitions
• Gross margin on cannabis sales expanded significantly to 46% from 16% in 2017 due to accelerating cannabis revenues combined with improved operating capacity
• Adjusted EBITDA of $(9.9) million for full year 2018 compared to $3.8 in 2017
• Strong capital position with $266.6 million cash on hand at year end, supported by a prudent capital allocation strategy focused on strategic acquisitions and rapid store expansion

2019 Year-to-Date Highlights

• Announced agreements to acquire Eureka in California and Acres in Nevada, strategically expanding to the West Coast with vertically integrated operations
• Completed transaction in Maryland that established vertical integration and expanded presence in the state
• Awarded one of forty processing licenses in Ohio
• Strengthened management team with hiring of experienced executives Neil Davidson, Chief Financial Officer, and Todd Goffman, General Counsel

“2018 was a landmark year for Curaleaf. We successfully completed the largest ever U.S. cannabis RTO, experienced substantial growth, and have firmly set the foundation to capitalize on the shift in public sentiment toward cannabis in the U.S. and capture key expansion opportunities in 2019,” said Joseph Lusardi, Chief Executive Officer of Curaleaf. Lusardi continued, “Curaleaf has become the most accessible national cannabis brand with the largest operational branded dispensary footprint in the country and the recent launch of our CBD line under Curaleaf Hemp. We’ve done this through our strategic presence in highly populated, limited license states, which has served as an important foundation for our aggressive expansion plan across the country. We continue to focus on providing the highest quality products and services for our customers.”

Neil Davidson, Chief Financial Officer of Curaleaf, added, “Curaleaf’s rapidly growing footprint is a direct result of our strong capital position, scaled operations and ability to strategically acquire assets that augment our existing platform. We remain focused on our path to profitability and positive cash flow, while maintaining a prudent use of capital to pursue acquisitions and organic growth initiatives that position us as a leader in the industry for the long term.”

Financial Results for the Fourth Quarter Ended December 31, 2018

Managed Revenue for the fourth quarter was $34.9 million, up 302% from the fourth quarter 2017 and 43% from the previous quarter, demonstrating accelerating revenue growth quarter-over-quarter throughout 2018.

Total Revenue for the fourth quarter of 2018 increased 408% year-over-year to $32.0 million, compared to $6.3 million in the fourth quarter of 2017. Revenue for the fourth quarter of 2018 increased 49% over the prior quarter.

Retail and wholesale revenue saw a six-fold increase to $23.7 million during the quarter, compared to $3.4 million in the fourth quarter of 2017. The increase in cannabis revenue was primarily due to the contribution from acquisitions made throughout 2017 and in 2018 as well as from new dispensaries that opened throughout the year, such as in Florida and New York.

Gross profit before impact of biological assets for the fourth quarter of 2018 was $20.0 million, compared to $4.6 million for the fourth quarter of 2017, resulting in gross margin of 63%. The increase was due to improved operating capacity of the Company’s cannabis business.

Gross profit on cannabis sales⁽¹⁾ was $11.8 million in the fourth quarter of 2018, resulting in a 50% margin, compared to $1.7 million in the fourth quarter of 2017.

Adjusted EBITDA was $(3.4) million for the fourth quarter of 2018, compared to $3.0 million for the fourth quarter of 2017.

Net loss for the fourth quarter of 2018 was $(16.5) million, compared to net income of $0.6 million in the fourth quarter of 2017 due to $4.2 million of one-time charges related to the RTO and acquisition and financing related expenses, an increase of $4.0 million in non-cash depreciation and amortization and share-based compensation and an increase in net interest expense of $2.0 million. Net loss per share for the fourth quarter of 2018 was $(0.04), compared to flat in the fourth quarter of 2017.

Financial Results for the Year Ended December 31, 2018

Full year 2018 Managed Revenue was $87.8 million, compared with $28.4 million in Managed Revenues for the full year 2017. The increase was primarily derived from organic growth in Florida, the opening of three dispensaries in New York and the acquisitions in Massachusetts in March and Arizona in April.

Total Revenue for full year 2018 increased 298% to $77.1 million, compared to $19.3 million in the year ended 2017. Retail and wholesale revenue increased 514% to $57.5 million, compared to $9.4 million.

Gross profit before impact of biological assets for the full year 2018 was $45.9 million, compared to $11.5 million for 2017, resulting in a gross margin of 60%. The significant increase was due to improved operating capacity of the Company’s cannabis business as acquisitions were integrated and new dispensaries opened.

Gross profit on cannabis sales were $26.4 million for the full year 2018, resulting in a 46% margin, compared to $1.5 million in the full year 2017.

Adjusted EBITDA amounted to $(9.9) million for the full year 2018, compared to $3.8 million for the full year 2017.

Net loss for the full year 2018 and 2017 was $(61.8) million and $(2.8) million, respectively. The net loss in 2018 includes a $25.1 million one-time, non-cash fair value adjustment as part of the RTO transaction as well as $7.8 million of one-time charges related to the RTO and acquisition and financing related expenses, an increase of $4.8 million in non-cash depreciation and amortization, share-based compensation, an increase in net interest expense of $3.9 million and an increase in operating expenses from an expanded management team, significantly increased headcount from operating markets in Florida, Connecticut, Nevada, Oregon and New York, and increased branding, lobbying, legal and other costs to expand the operations. These costs were largely offset by Curaleaf’s growing revenue base from organic expansion and acquisition integration.

Net loss per share for the full year 2018 was $(0.16), compared to $(0.01) for the full year 2017.

Balance Sheet and Liquidity

On October 29, 2018, the Company received net proceeds of approximately $380 million from the completion of its private placement offering. As of December 31, 2018, the Company had $266.6 million of cash.

Voluntary Extension of Lock-up Agreements

On March 20, 2019, the Company founders and other key shareholders have entered into voluntary lock-up agreements with the Company in respect of 249,037,550 subordinate voting shares and 122,170,705 multiple voting shares. This represents 81% of the total shares outstanding. The voluntary lock-up agreements stipulate that these shareholders will not sell, directly or indirectly, any Curaleaf securities without Company approval prior to October 20, 2019.

Outlook for Full Year 2019

The Company reaffirmed its full year 2019 outlook for Managed Revenue of $400 million and free cash flow of $100 million.

Curaleaf plans to continue growth of its operations via expansion in three dimensions: acquiring licenses in limited license markets, increasing presence in current markets, and increasing exposure in mass markets. The Company expects acquisition related costs, marketing and selling expenses, and capital expenditures to increase as it expands its presence in current markets and expands into new markets.

The guidance for fiscal 2019 is based on a number of assumptions, including:

• The successful execution and implementation of a business strategy that allows the Company to increase its retail store footprint by the end of 2019 and expand its current cultivation and manufacturing capacity and yield.
• Increase of same store sales at existing retail dispensaries.
• Receive the appropriate regulatory approvals on the Company’s acquisitions signed in 2018.
• Continued forward momentum of the regulatory landscape in the U.S.
• The absence of a significant shift in economic conditions or material changes in the retail competitive environment.

The foregoing assumptions, although considered reasonable by the Company on March 20, 2019 may prove to be inaccurate. Accordingly, the Company’s results could differ materially from the Company’s expectations as set forth in this press release.

Conference Call and Webcast Information

Curaleaf will host a conference call and audio webcast on March 20, 2019 at 4:30 pm ET to answer questions about the Company’s operational and financial highlights. The dial-in numbers for the conference call are +1-877-407-9039 (U.S. Toll-Free) or +1-201-689-8470 (International). Please dial-in 10 to 15 minutes prior to the start time of the conference call and an operator will register your name and organization.

The conference call will also be available via webcast, which can be accessed through the Investor Relations section of Curaleaf’s website, https://ir.curaleaf.com/ir-calendar.

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until April 3, 2019 at 11:59 pm ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13688116. The online archive of the webcast will be available on https://ir.curaleaf.com/ir-calendar for 30 days following the call.

¹ Total Revenue and Managed Revenue excludes the impact of pending acquisitions.
² See “Non-IFRS Financial and Performance Measures” below for more information regarding Curaleaf’s use of Non-IFRS financial measures and other reconciliations.

Supplemental Financial Statement Excerpts

Highlights from Statements of Profits and Losses (Unaudited)
($ thousands, except for per share amounts)

Highlights from Statements of Financial Position and Cash Flows (Unaudited)
($ thousands)

Non-IFRS Financial and Performance Measures

In this press release Curaleaf refers to certain non-IFRS financial measures such as Managed Revenue, Gross Profit on Cannabis Sales and Adjusted EBITDA. These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers. Curaleaf defines Managed Revenue as total revenue plus revenue from entities for which the Company has a management contract but does not consolidate the financial results based on IFRS 10 – Consolidated Financial Statements. The Company defines Gross Profit on Cannabis Sales as retail and wholesale revenues less cost of goods sold. Adjusted EBITDA is defined by Curaleaf as earnings before interest, taxes, depreciation and amortization less share-based compensation expense and one-time charges related to the Company’s RTO and acquisition and financing related costs. Curaleaf considers these measures to be an important indicator of the financial strength and performance of our business. The following tables provide a reconciliation of each of the non-IFRS measures to its closest IFRS measure.

Managed Revenue
($ thousands)

Gross Profit on Cannabis Sales
($ thousands)

Adjusted EBITDA
($ thousands)

About Curaleaf Holdings

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) is the leading vertically integrated multi-state cannabis operator in the United States. It is a high-growth cannabis company with a national brand known for quality, trust and reliability. The company is positioned in highly populated, limited license states, and currently operates in 12 states with 42 dispensaries, 12 cultivation sites and 11 processing sites. Curaleaf has the executive expertise and research and development capabilities to provide leading service, selection, and accessibility across the medical and adult-use markets, as well as the CBD category through its Curaleaf Hemp brand.

Investor Contact:

Curaleaf Holdings, Inc.
Christine Rigby, SVP, Investor Relations
IR@curaleaf.com

Media Contact:

Teneo
Megan Bishop, SVP
Media@curaleaf.com

Cautionary Note Regarding Forward-Looking Statements and Future-Oriented Financial Information

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of Canadian securities laws and United States securities laws (“forward-looking statements”). Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management’s current beliefs, expectations or assumptions regarding the future of the business, future plans and strategies, operational results and other future conditions of the Company. In addition, the Company may make or approve certain statements in future filings with Canadian securities regulatory authorities, in press releases, or in oral or written presentations by representatives of the Company that are not statements of historical fact and may also constitute forward-looking statements. All statements, other than statements of historical fact, made by the Company that address activities, events or developments that the Company expects or anticipates will or may occur in the future are forward-looking statements, including, but not limited to, statements preceded by, followed by or that include words such as “assumptions”, “assumes”, “guidance”, “outlook”,  “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words and includes, among others, information regarding: its outlook for 2019; expected 2019 pro forma revenues, free flow cash and other financial results; growth of its operations via expansion, for the effects of any transactions; expectations for the potential benefits of any transactions; statements relating to the business and future activities of, and developments related to, the Company after the date of this press release, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company’s business, operations and plans; expectations that planned acquisitions will be completed; expectations regarding cultivation and manufacturing capacity; expectations regarding receipt of regulatory approvals; expectations that licenses applied for will be obtained; potential future legalization of adult-use and/or medical cannabis under U.S. federal law; expectations of market size and growth in the U.S. and the states in which the Company operates; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the cannabis industry generally; and other events or conditions that may occur in the future. Forward-looking statements may relate to future financial conditions, results of operations, plans, objectives, performance or business developments. These statements speak only as at the date they are made and are based on information currently available and on the then current expectations. Holders of securities of the Company are cautioned that forward-looking statements are not based on historical facts but instead are based on reasonable assumptions and estimates of management of the Company at the time they were provided or made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the available funds of the Company and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the cannabis industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the cannabis industry; risks related to contracts with third-party service providers; risks related to the enforceability of contracts; reliance on the expertise and judgment of senior management of the Company, and ability to retain such senior management; risks related to proprietary intellectual property and potential infringement by third parties; the concentrated voting control of the Company’s Chairman and the unpredictability caused by the capital structure; risks relating to the management of growth; increasing competition in the industry; risks inherent in an agricultural business; risks relating to energy costs; risks associated to cannabis products manufactured for human consumption including potential product recalls; reliance on key inputs, suppliers and skilled labor; cybersecurity risks; ability and constraints on marketing products; fraudulent activity by employees, contractors and consultants; tax and insurance related risks; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; risks related to future acquisitions or dispositions; sales by existing shareholders; limited research and data relating to cannabis; as well as those risk factors discussed under “Risk Factors” in the Company’s Listing Statement dated October 26, 2018 and as described from time to time in documents filed by the Company with Canadian securities regulatory authorities. The purpose of forward-looking statements is to provide the reader with a description of management’s expectations, and such forward-looking statements may not be appropriate for any other purpose. In particular, but without limiting the foregoing, disclosure in this press release as well as statements regarding the Company’s objectives, plans and goals, including future operating results and economic performance may make reference to or involve forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. You should not place undue reliance on forward-looking statements contained in this press release. Such forward-looking statements are made as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The Company’s forward-looking statements are expressly qualified in their entirety by this cautionary statement.

SOURCE Curaleaf Holdings, Inc.

VANCOUVER, March 21, 2019 /CNW/ – Zenabis Global Inc. (“Zenabis”) (TSXV: ZENA) today announced a significant expansion of its supply opportunity through its entrance into the European pharmaceutical cannabis market. Zenabis has entered into a Letter of Intent (“LOI”) towards a definitive supply arrangement with Farmako GmbH (“Farmako”), a research-based pharmaceutical company headquartered in Frankfurt, Germany.

Pursuant to the LOI, Farmako has committed to an initial purchase of CBD isolate. Farmako and Zenabis will each pursue all relevant regulatory permits and licenses in order to complete the initial transaction. The Letter of Intent also contemplates an expansion of the supply arrangement to include other Zenabis products as permitted under applicable laws.

“We are thrilled to enter the European market alongside such an innovative and ambitious industry leader as Farmako,” said Andrew Grieve, Chief Executive Officer of Zenabis. “The market for pharmaceutical cannabis in Europe is estimated to reach €55 billion by 2028, and this strategic relationship helps position our company to seize the opportunity this represents. Farmako’s significant growth ambitions align with our own. With a shared commitment to product innovation and R&D, we look forward to leveraging this relationship to expand our opportunities in the future.”

Farmako founder and Chief Executive Officer, Niklas Kouparanis, said “Farmako has the explicit goal to be the gateway to Europe for pharmaceutical cannabis. We are delighted that Zenabis and Farmako are beginning to cooperate, and that the first shipment of CBD isolate was initiated today. We are pursuing operations in every market that provides the necessary legal basis, and we believe that Zenabis with its expanding high-capacity growing facilities will be of significant benefit to the pursuit of our objectives.”

With an overall population of over 740 million, Europe will be the largest pharmaceutical cannabis market worldwide. The two largest European economies, Germany and the United Kingdom, passed legislation allowing the prescription of pharmaceutical cannabis in March 2017 and November 2018 respectively.

About Zenabis

Zenabis is a significant licensed cannabis cultivator of medical and adult use cannabis, and employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta and Langley, B.C.; and Stellarton, Nova Scotia. In addition to gaining technologically advanced knowledge of plant propagation, the recent addition of state-of-the-art greenhouses in Langley provides Zenabis with 3.5 million square feet of facility space that can, upon full conversion, be dedicated to cannabis production.

If all facility space is fully built out and dedicated to production, Zenabis will own, and have access to, 660,000 square feet of high quality indoor cannabis production space, as well as 2.1 million square feet of greenhouse space at its Langley facility (an additional 700,000 square feet of greenhouse space will be used to continue the existing propagation business, to be converted at such a time that is beneficial to the strategic position of the company), strategically positioned on Canada’s coasts. These facilities, if fully converted for cannabis production, would have the design capacity to yield 479,300 kg of dried cannabis annually, for both national and international market distribution. The Zenabis brand name is used among the medical market, while Namaste is used to service the adult use market.

The management team at Zenabis has significant experience in finance, agriculture, technology, pharmaceutical sales, consumer packaged goods, international distribution and brand marketing.

Zenabis has established distribution relationships with provincial liquor authorities, wholesalers and licensed retailers in 9 provinces and territories (British Columbia, Alberta, Saskatchewan, Manitoba, Quebec, New Brunswick, Nova Scotia, Prince Edward Island and the Yukon Territory).

Forward Looking Information

This news release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding obtaining the required permits to complete the initial transaction and future transactions; entering into a definitive agreement; expanding the supply arrangement to include other products; the future plans, costs, objectives or performance of Zenabis, or the assumptions underlying any of the foregoing. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Zenabis’ control. These risks, uncertainties and assumptions include, but are not limited to, those described Zenabis Management Information Circular dated November 23, 2018, a copy of which is available on SEDAR at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Furthermore, any forward-looking information with respect to available space for cannabis production is subject to the qualification that management of Zenabis may decide not to use all available space for cannabis production, and the assumptions that any construction or conversion would not be cost prohibitive, required permits will be obtained and the labour, materials and equipment necessary to complete such construction or conversion will be available. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Zenabis does not intend, nor undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws.

For more information, visit: https://www.zenabis.com.

SOURCE Zenabis Global Inc.

For further information: Media Relations: media@zenabis.com, 1-844-523-8679; Investor Relations: Shobana Thaya, Zenabis Global Inc., Invest@zenabis.com, 1-844-523-8679; Andrew Grieve, Chief Executive Officer, 1-855-936-2247

Related Links

https://www.zenabis.com/

VANCOUVER and DENVER, March 20, 2019 /CNW/ – AgraFlora Organics International Inc. (“AgraFlora“) (the “Company“) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: PUFXF), a growth oriented and diversified international cannabis company, is pleased to announce it has initiated due diligence with respect to a potential partnership with Dixie Brands Inc. (“Dixie”) (CSE: DIXI.U) (OTC: DXBRF) (Frankfurt: 0QV), relating to the manufacture, sale and distribution of cannabis infused products within legalized markets in the European Union (the “EU”). AgraFlora and Dixie have identified various synergies that exist across product portfolios and distribution networks and are assessing opportunities to capture market share in the EU to the mutual benefit of both companies.

“Our goal is to become one of the leading global CPG companies in the cannabis industry, known around the world for our broad portfolio of great tasting high-quality branded products,” said Chuck Smith, President of Dixie Brands. “The European Union is a significant opportunity with more and more countries embracing medical cannabis and cannabis-based products. By exploring these opportunities with AgraFlora, we can leverage our experience in the United States to bring high-quality products to the European market.”

“Dixie has been producing award-winning cannabis-infused products for almost ten years and the Dixie brand has become a household name amongst cannabis consumers in the United States,” said Derek Ivany, President and CEO of AgraFlora Organics. “We are eager to explore opportunities that bring AgraFlora’s production capabilities together with this leading cannabis consumer brand to the rapidly growing European marketplace. I have a strong personal belief that the extensive product portfolio and brand recognition that Dixie has built in the U.S. will garner significant support in the EU. Chuck Smith, the President and CEO of Dixie, is a well-respected pioneer in cannabis industry and we at AgraFlora are enthusiastic about the opportunity to work alongside him and his team.”

With a population in excess of 500 million citizens, the EU represents a significant share of the global legalized cannabis market. France, the UK, and Spain are reviewing current legislation, while Germany, Italy, and the Netherlands are focusing on expanding existing medical programs. This has led industry reports to suggest Europe is likely to become the world’s largest legal cannabis market in the next five years. According to a research report by Prohibition Partners, the cannabis market in the EU may represent as much as €123 billion by 2028.

About Dixie Brands Inc.

Dixie Brands, through its licensed partners, has been formulating award-winning THC and CBD-infused products since 2009, and is expecting to double its manufacturing and distribution capabilities in 2019 in the U.S. as well as expand internationally, including Canada and Latin America. Dixie leads the global industry in the development, packaging design, product innovation and quality control for the commercial production of cannabis infused products. While Dixie started with a single flagship product, the Dixie Elixir (a THC-infused soda), it is now one of the industry’s most recognized consumer brands, expanding to over 100 products across more than 15 different product categories representing the industry’s finest edibles, tinctures, topicals and connoisseur grade extractions, as well as world-class CBD-infused wellness products and pet dietary supplements. Dixie’s executive team has been instrumental in the formation of the cannabis industry for recreational and medicinal use, serving as founding members on several national regulatory and business-oriented industry organizations.

 About AgraFlora Organics International Inc.

AgraFlora Organics International Inc. is a growth oriented and diversified company focused on the international cannabis industry. It owns an indoor cultivation operation in London, ON and is a joint venture partner in Propagation Service Canada Inc. and its large-scale 2,200,000 sq. ft. greenhouse complex in Delta, BC. The Company has a successful record of creating shareholder value and is actively pursuing other opportunities within the cannabis industry. For more information please visit: www.agraflora.com.

ON BEHALF OF THE BOARD OF DIRECTORS

Derek Ivany
President & CEO

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.

SOURCE AgraFlora Organics International Inc.

For further information: AgraFlora Organics International Inc., Tim McNulty, E: ir@agraflora.com, T: (800) 783-6056; For French inquiries: Remy Scalabrini, Maricom Inc., E: rs@maricom.ca, T: (888) 585-MARI; Dixie Brands: Corporate: C.J. Chapman, General Counsel, T: +1 (303) 945-3963, E: cchapman@dixiebrands.com; Investors: Jeff Codispodi, Vincic Advisors, T: +1 (647) 278-9376, E: jeff@vincicadvisors.com; Media: Georgia Jablon, DIVIDE, T: +1 720-598-0998, E: Georgia.Jablon@wearedivide.com

Related Links

www.pufventures.com

TORONTO and LOS ANGELES, March 21, 2019 (GLOBE NEWSWIRE) — The Tinley Beverage Company Inc. (the “Company” or “Tinley”) is pleased to announce that it has completed its planned expansion of the bottling facility in the Coachella Valley, California (the “Phase 2 Facility”) to produce Tinley’s great-tasting cannabis infused beverages.  This facility can now produce up to 3 million bottles per year, and the Company projects an average wholesale price of US$3-US$4/bottle for its single-serve beverages and US$15-US$17/bottle for its multi-serve beverages.  The next-generation versions of Tinley’s acclaimed cocktail-inspired, non-alcoholic cannabis beverages are intended to go into production at this expanded facility for delivery to stores in April.  These next-generation products contain updated cannabis solubalization technology, clean label claims and packaging that complies with new California regulations.

The Company is also pleased to announce that it remains on schedule to complete the build-out and installation of a state-of-the-art bottling line at its flagship bottling plant (the “Phase 3 Facility”) in Long Beach, California by the end of the second quarter of 2019.  Tinley’s flagship Phase 3 Facility will have bottling capacity of approximately 12 million bottles per year, with a space plan for up to two additional bottling lines to accommodate additional beverage formats and capacity as required.  The Phase 3 Facility will also be home to Tinley’s purpose-built beverage distribution facility, which will allow Tinley to execute a controlled DSD distribution model and capture additional economics from this downstream phase of the value chain.  Upon licensing of the Phase 3 Facility, Tinley intends to move the bottling line in the Phase 2 Facility to one of its priority expansion jurisdictions elsewhere in North America.  The Company continues to caution, however, that the timing of full licensing of the Phase 3 facility remains uncertain, and that, like any consumer products company, anticipated revenue is a function of consumer demand, not of the Company’s production capacity.

The Company expects to commence production of $200,000 worth of the next-generation Margarita and Moscow Mule-inspired, non-alcoholic cannabis-infused beverages.  This quantity reflects backordered and indicated demand from distributors to date in 2019.  All beverages produced in this run are expected to be shipped to stores during the month of April.  The Company will then immediately focus on the production of its non-alcoholic Tinley ’27 products, which are inspired by Cinnamon Whisky, Amaretto and Rum.

As previously disclosed, California’s cannabis regulators began making requests in late 2018 for modifications to the Company’s packaging to reflect anticipated 2019 regulations.  As a result, Tinley elected to pause production to accommodate the upgrade and expansion of the Phase 2 Facility, while making the required packaging modifications.  During this time, Tinley also implemented newer beverage technology that allows for faster onset and offset times, visual clarity and a greater full-flower Sativa effect.  Tinley selected this technology out of 13 candidate technology suppliers, and integrated it with the Company’s own technologies, methods and flavor systems.  The updated products are vegan, gluten free, and contain as little as 1g of sugar per serving.  These products were designed based on the significant amount of intellectual property that Tinley accumulated via the initial versions of these products.  This IP includes learnings on consumer purchase and consumption habits for various types of cannabis beverages, as well as SOPs for scaled cannabis beverage production.

“We’re excited to be launching our next-generation products, with a significant amount of dispensary demand already in hand as a result of the positive consumer response we received for our initial products.  We believe that Tinley is the first-mover with liquor-inspired, non-alcoholic beverages that contain cannabis 2.0 solubalization technology,” said Rick Gillis, President, Tinley Western USA.

About The Tinley Beverage Company

The Tinley Beverage Company (Santa Monica, California) created the Tinley Tonics, Tinley ‘27 and Hemplify® line of cannabis and hemp CBD beverages.  The Hemplify® CBD beverages are available in mainstream stores in California, while the Tinley Tonics and Tinley ’27 line of liquor-inspired, non-alcoholic, cannabis-infused beverages are available in dispensaries throughout the State.  The Company is also building a 20,000 square foot cannabis beverage manufacturing and distribution facility in Long Beach, California.

Forward-Looking Statements

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This press release contains or refers to forward-looking information and is based on current expectations that involve a number of business risks and uncertainties. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects and the other risks involved in the mineral exploration and development industry. Forward-looking statements are subject to significant risks and uncertainties, and other factors that could cause actual results to differ materially from expected results. Readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by law.

Products, formulations and timelines outlined herein are subject to change at any time.  All figures CAD unless otherwise indicated.

For further information on The Tinley Beverage Company, please contact:

The Tinley Beverage Company Inc.
3435 Ocean Park Blvd. #107
Santa Monica, CA  90405
(310) 507-9146
info@drinktinley.com
Twitter: @drinktinley
Instagram: @tinleybeverage
www.drinktinley.com
OTCQX:TNYBF  CSE:TNY

VANCOUVER, March 21, 2019 /CNW/ – Nextleaf Solutions Ltd. (formerly Legion Metals Corp.) (“Nextleaf” or the “Company“) (CSE: OILS) is pleased to announce that the common shares of Nextleaf commence trading today on the Canadian Securities Exchange (the “CSE“) under the ticker symbol “OILS“. Nextleaf is an extraction and processing technology company that has developed a portfolio of issued and pending patents pertaining to the company’s unique, industrial-scale process of producing purified cannabinoid distillate, a tasteless, odourless cannabis concentrate best suited for infusing premium value-added products.

“I firmly believe Nextleaf’s intellectual property portfolio for improving the purity and yield of cannabinoids obtained through the extraction and purification of cannabis biomass will be extremely impactful with the global legalization of cannabis and rapidly growing demand for oils and derivative products in medical and adult-use markets” says CEO Paul Pedersen.

Nextleaf Solutions Management Team

Paul Pedersen, Chief Executive Officer and Director
Mr. Pedersen has been focused on the cannabis industry since 2013, consulting for a variety of cannabis companies and investors including Canada’s first licensed cannabis oil producer. He has founded several startups over his career, including a media company acquired in 2007 by Towerstream Corporation (NASDAQ: TWER). Paul holds a MBA in Finance from the Eli Broad Graduate School of Management at Michigan State University and a Bachelor of Commerce Degree from the Sobey School of Business at Saint Mary’s University.

Charles Ackerman, Chief Financial Officer and Director
Mr. Ackerman is a Chartered Accountant who has successfully led mergers and acquisitions, divestitures and private and public capital raises. He has served in a number of finance and corporate leadership roles developing and executing growth strategies, with private and public companies and family offices across Canada. Charles previously consulted for Canada’s first non-incumbent federally licensed commercial medical cannabis producer. Charles holds a Bachelor of Commerce Degree from the Sobey School of Business at Saint Mary’s University.

Ryan Ko, Chief Technology Officer
Through his extensive career in the legal cannabis industry, Mr. Ko has developed deep expertise and intellectual property within extraction technology, leading to Canada’s first processing patent for cannabis extraction and purification. Mr. Ko leads the development of Nextleaf’s proprietary cannabis processing technology.

About Nextleaf Solutions

Nextleaf Solutions Ltd. (CSE: OILS) is an extraction technology company that has developed a portfolio of issued and pending patents pertaining to the company’s unique, industrial-scale process of producing purified cannabinoid distillate, a tasteless, odourless cannabis concentrate best suited for infusing premium value-added products. Nextleaf plans to commercialize its intellectual property portfolio by providing B2B processing services to licensed cultivators and supplying cannabis oil and extracts to qualified Canadian and international partners under the client’s own brands. Nextleaf has completed construction of its dedicated extraction and processing facility in Greater Vancouver, British Columbia, in time for Canada’s legalization of edibles and other cannabis derivative products. The Company’s processing facility includes research and laboratory infrastructure, allowing for the continued development of novel, scalable cannabis processing technology and intellectual property.

For more information about Nextleaf Solutions (CSE: OILS) visit  www.nextleafsolutions.com or follow Nextleaf across social media platforms.

Contacts

Adel Fares, Investor Relations
604-283-2301 (ext. 201)
investors@nextleafsolutions.com

Paul Pedersen, CEO
604-347-9160
paul@nextleafsolutions.com

ON BEHALF OF THE BOARD OF NEXTLEAF SOLUTIONS LTD.

“Paul Pedersen”
Paul Pedersen, CEO

This press release contains “forward-looking information” that is based on the Company’s current expectations, estimates, forecasts and projections. This forward-looking information includes, among other things, the Company’s business, plans, outlook and business strategy. The words “may”, “would”, “could”, “should”, “will”, “likely”, “expect,” “anticipate,” “intend”, “estimate”, “plan”, “forecast”, “project” and “believe” or other similar words and phrases are intended to identify forward-looking information. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.

The CSE has not reviewed, approved or disapproved the contents of this press release.

To contact Nextleaf Solutions email investors@nextleafsolutions.com or call 604-283-2301 (ext. 201)

SOURCE Nextleaf Solutions Ltd.

Related Links

https://www.nextleafsolutions.com

The Hemp Biz Conference is pleased to announce the Michigan Hemp Symposium in partnership with local Michigan cannabis business education leader Cannabiz Connection. The Michigan Hemp Symposium will be held on March 23rd at the Crossroads Conference Center, Grand Rapids, Michigan.

Agenda highlights include: Farm Bill and MDARD update from Thomas Lavigne of Cannabis Counsel, A two hour keynote on growing hemp from a hemp farmer with 3 years cultivation experience in both Colorado and New York and a update on CBD legislation from State Rep Steven Johnson.

The passage of the 2018 Farm Bill allows farmers to cultivate hemp legally across the U.S. for the first time in 81 years. Farm Bill legislation clarifies three important points to jump start this new industry; It defines hemp as a regular agricultural crop, (containing 0.3% or less of THC, the compound responsible for the “high” associated with cannabis), it updates the Controlled Substances Act to effectively legalize products containing cannabidiol (or CBD, which is derived from hemp but does not cause psychotropic effects associated with marijuana); and it allows hemp farmers to obtain federal crop insurance, providing a major safety net that was previously unavailable for hemp commodity crop farmers.

“The hemp industry is faced with great challenges as we build the supply chain.  As a result of these challenges, The Hemp Biz Conference has developed the Hemp Symposium Series in collaboration with state-level partners to deliver content from state-level regulatory leaders, farmers and manufacturers with multiple years of hemp production experience.” said Christie Lunsford, CEO of The Hemp Biz Conference. “We are proud to have partnered with Cannabiz Connection to deliver  in-depth regulatory information and unique perspectives from top hemp business leaders working to develop the next great American industry,”

HEMP MARKET SIZE

According to Grand View Research, “North America is expected to exhibit a CAGR of 16.9% from 2018 to 2025. This growth is attributed to rising demand for hemp products in oil, seedcake, food, beverage, fiber and personal care products.

ABOUT CANNABIZ CONNECTION

Cannabiz Connection  is a comprehensive, one-stop-shop for business owners looking to start-up or grow their business in the hemp and cannabis industries.. Cannabiz Connection is a community-building platform providing education, as well as a place to connect with other like-minded business owners and entrepreneurs, empowering each other to build stronger connections that thrive in an already burgeoning industry, nationwide. More than a directory, Cannabiz Connection is a social network and business accelerator, all built into one platform. Cannabiz Connection offers weekly networking events throughout the state. For more information, visit http://www.cannabizconnection.com.

ABOUT HEMP SYMPOSIUM SERIES

The Hemp Symposium Series is a one day hemp education symposium focused on jump starting state level hemp agricultural communities in partnership with local business leaders and hemp advocates.  With up to date information on industrial hemp cultivation, implications of the Farm Bill and regulatory updates specific to their state and overview of business opportunities in the developing industry.

For more information and to explore the Hemp Symposium Series Dates and Locations please visit

https://thehempbizconference.com/symposiums/.

ABOUT THE HEMP BIZ CONFERENCE

The Hemp Biz Conference supports the growth of the hemp industry by bringing together industry professionals, policy makers and investors to develop a sustainable commodity supply chain in a professional B2B environment. Our focus is an exploration of new hemp technologies that will reframe our understanding of the world in agriculture, processing, manufacturing, extraction, food, medicine, textiles, plastics and bio-fuel.

For more information and to explore The Hemp Biz Conference May 1st and 2nd, 2019 please visit https://thehempbizconference.com/.

For more information, please contact:

The Hemp Biz Conference, LLC, Christie Lunsford, CEO, E-mail: jointhefuture@thehempbizcon.com

Cannabiz Connection, Jamie Cooper, Founder, E-mail:

jamie@cannabizconnection.com

Advance media registration is available for qualified reporters working full time for print, broadcast and web publications with valid press credentials. To register, please contact jointhefuture@thehempbizcon.com.

The post The Hemp Biz Conference™ Announces the Michigan Hemp Symposium™ in partnership with Cannabiz Connection appeared first on CannabisFN.

MINNEAPOLIS, March 20, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the Company”), America’s leading science-focused multi-state cannabis company, is pleased to announce that effective at market open today, the company will begin trading on the Canadian Securities Exchange (the “CSE”) under the ticker symbol “VREO.”

“Today is an historic milestone for Vireo Health,” said Chief Executive Officer, Kyle Kingsley, M.D. “Our business and product offerings are expanding rapidly, and we expect the proceeds from our RTO transaction will enable us to significantly expand our geographic footprint and our investments in intellectual property development. We are proud of our track record of creating value for shareholders over time, and our board of directors and executive management team will continue to prioritize this important goal as we transition to operating as a public company.”

“We believe that science will drive the lion’s share of long-term opportunity in the cannabis industry. From novel, efficient, scaled processing equipment, to proprietary consumer products and our expansive intellectual property portfolio, Vireo has positioned itself as the cannabis company of the future,” Dr. Kingsley said.

Dr. Kingsley continued, “Vireo has been pursuing a business model consistent with this vision since its inception, and our leadership team is committed to achieving this objective. We also believe that customer service excellence will be key toward winning and maintaining market share, and we look forward to leveraging our proprietary e-commerce and home delivery platforms to meet the highly-demanding needs of today’s modern consumer landscape.”

In conjunction with the previously-announced business combination with Darien Business Development Corp., Vireo Health International, Inc. raised more than US $50 million through a brokered and non-brokered private placement offering. Concurrent with the public listing, the Company launched its new investor relations website at investors.vireohealth.com.

About Vireo Health International, Inc.

Vireo Health International, Inc. is America’s leading science-focused, multi-state cannabis company. Vireo’s physician-led team of more than 250 employees is dedicated to providing best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company currently has operations in six states including Minnesota, New York, Pennsylvania, Maryland, Rhode Island, and Ohio.

Contact Information 

For more information about the company, please visit www.vireohealth.com or contact:

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

The CSE has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Statement Disclosure

This news release contains forward-looking information within the meaning of applicable securities laws, based on current expectations. Generally, any statements that are not historical facts may contain forward-looking information, and forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “look forward to”, “budget” “scheduled”, “estimates”, “forecasts”, “will continue”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or indicates that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, “occur” or “be achieved.” Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Vireo, and includes statements about, among other things, future developments, the future operations, strengths and strategy of the Company. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results. These statements are based upon certain material factors, assumptions and analyses that were applied in drawing a conclusion or making a forecast or projection, including Vireo’s experience and perceptions of historical trends, current conditions and expected future developments, as well as other factors that are believed to be reasonable in the circumstances.

Examples of the assumptions underlying the forward-looking statements contained herein include, but are not limited to those related to: the achievement of goals, the close of all acquisitions, obtaining of all necessary permits and governmental approvals, future market positioning, as well as expectations regarding availability of equipment, skilled labor and services needed for cannabis operations, intellectual property rights,  development, operating or regulatory risks, trends and developments in the cannabis industry, business strategy and outlook, expansion and growth of business and operations, the timing and amount of capital expenditures; future exchange rates; the impact of increasing competition; conditions in general economic and financial markets; access to capital; future operating costs; government regulations, including future legislative and regulatory developments involving medical and recreational marijuana and the timing thereto; receipt of appropriate and necessary licenses in a timely manner; the effects of regulation by governmental agencies; the anticipated changes to laws regarding the recreational use of cannabis; the demand for cannabis products and corresponding forecasted increase in revenues; and the size of the medical marijuana market and the recreational marijuana market.

Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. Vireo assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

By its nature, forward-looking information is subject to risks and uncertainties, and there are a variety of material factors, many of which are beyond the control of the Company and that may cause actual outcomes to differ materially from those discussed in the forward-looking statements. These factors include, but are not limited to: denial or delayed receipt of all necessary consents and approvals; need for additional capital expenditures; increased costs and timing of operations; unexpected costs associated with environmental liabilities; requirements for additional capital; reduced future prices of cannabis; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the cannabis industry; delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities; title disputes; claims limitations on insurance coverage; risks related to the integration of acquisitions; fluctuations in the spot and forward price of certain commodities (such as diesel fuel and electricity); changes in national and local government legislation, taxation, controls, regulations and political or economic developments in the countries where the Company may carry on business in the future;  liabilities inherent in cannabis operations;  risks relating to medical and recreational cannabis; cultivation, extraction and distribution problems; competition for, among other things, capital, licences and skilled personnel;  risks relating to the timing of legalization of recreational cannabis; changes in laws relating to the cannabis industry; and management’s success in anticipating and managing the foregoing factors.

The post Multi-State Cannabis Company Vireo Health to Begin Trading on the Canadian Securities Exchange Under Ticker Symbol “VREO” appeared first on CannabisFN.

DIONYMED BRANDS INC. SIGNS BINDING TERM SHEET TO ACQUIRE 1.83 ACRE SOUTHERN CALIFORNIA CANNABIS CAMPUS FROM MMAC

DionyMed Strengthens Distribution and Direct-to-Consumer Platform in the Los Angeles Market

DionyMed Brands Inc. (“DionyMed” or “Company”) (CSE: DYME), a multi-state cannabis brands platform, announced today it has signed a binding term sheet with MM Esperanza 2 LLC, doing business as “MMAC,” to acquire select MMAC assets (the “Acquisition”), including the 1.83 acre Los Angeles cannabis campus that includes a dispensary storefront, distribution facility, manufacturing hub and direct-to-consumer fulfillment center. The acquisition includes all property, leaseholds, equipment and licenses for a purchase price of USD$19,000,000 and enhances DionyMed’s brands distribution and direct-to-consumer footprint in Southern California.

Completion of this arms-length acquisition is subject to several conditions, including, but not limited to, the execution and delivery of definitive documentation mutually agreeable to the parties, completion of due diligence on MMAC to the Company’s sole satisfaction and receipt of all board, shareholder, regulatory and third-party approvals for the Acquisition.

Located in the heart of Los Angeles, MMAC’s 1.83 acre campus serves the Southern California cannabis market with a well-established retail storefront, a distribution, manufacturing, and direct-to-consumer fulfillment center supporting all of Los Angeles County. Under the terms of the agreement, DionyMed will pay MMAC USD$13,000,000 in cash, subject to financing, and USD$6,000,000 in DionyMed Common Shares.

Edward Fields, CEO of DionyMed, commented, “This acquisition accelerates the DYME brands portfolio in the world’s largest cannabis market – California. Together, with our existing Northern California footprint, this market leading cannabis campus supports our vision for bringing safe, trusted cannabis brands to consumers throughout the entire state.”

Cameron Smith, COO of MMAC, commented, “Now that we’ve established our Los Angeles platform, the sale of the property provides MMAC additional working capital to quickly expand its footprint beyond the Los Angeles area. Further, by partnering with DionyMed, one of the top operators in the cannabis industry, we can utilize their efficient direct-to-consumer cannabis platform to drive increased awareness of our brands.”

To be added to the DionyMed e-mail distribution list, please e-mail DionyMed@kcsa.com with DionyMed in the subject line.

About DionyMed
Founded in 2017, DionyMed is a multi-state cannabis brands, distribution and delivery platform, supporting cultivators, manufacturers and award-winning brands in the medical and adult-use cannabis markets. DionyMed sells branded products in every category from flower to vape cartridges, concentrates and edibles. DionyMed serves more than 700 dispensaries and completes over 40,000 Direct-To-Consumer deliveries each month with its growing portfolio of products and brands. Learn more at www.DionyMed.com and follow @DYME_Inc on Twitter and LinkedIn.

Forward-Looking Information and Statements
This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved” and include, without limitation, statements related to the structure of the acquisition, the ability of DionyMed and MMAC to complete the acquisition and the satisfaction or waiver of the conditions precedent, the method of payment of consideration for the assets of MMAC and the impact of the acquisition on DionyMed and MMAC.

In connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions, including but not limited to: the Company being able to complete the acquisition in the matter set out herein, the Company and MMAC being able to execute and deliver definitive documentation, there being no material issues in the due diligence on MMAC, the Company and MMAC being able to obtain all board, shareholder, regulatory and third-party approvals, there being no material impact on the businesses of DionyMed or MMAC, the ability of the Company or MMAC to complete the transaction and obtain the necessary approvals.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements, including but not limited to: the Company or MMAC not being able to complete the acquisition on the terms described herein or at all, the acquisition not having the desired impact or there being a material adverse change in the business of MMAC, material changes in the Company’s business plan that would affect the use of proceeds as set out herein, there being material fluctuations in the Company’s share price and certain other risk factors set out in the Listing Statement of the Company available on the Company’s profile on SEDAR at www.sedar.com.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190320005411/en/

The post CORRECTING AND REPLACING DionyMed Brands Inc. Signs Binding Term Sheet to Acquire 1.83 Acre Southern California Cannabis Campus from MMAC appeared first on CannabisFN.